Meiragtx Holdings Plc (MGTX)

Mar 25, 2025, 10:50 AM EDT - 25 days ago

MeiraGTx Holdings: Gaining Regulatory Focus

Mar 13, 2025, 9:51 AM EDT - 5 weeks ago

MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars

Mar 13, 2025, 8:00 AM EDT - 5 weeks ago

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

Mar 13, 2025, 7:30 AM EDT - 5 weeks ago

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process

Feb 21, 2025, 6:30 AM EST - 2 months ago

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

Jan 22, 2025, 4:09 PM EST - 3 months ago

MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value

Jan 22, 2025, 8:30 AM EST - 3 months ago

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

Dec 3, 2024, 2:18 PM EST - 4 months ago

MeiraGTx Holdings: Behind The Recent Rally

Oct 15, 2024, 1:32 PM EDT - 6 months ago

MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings

Oct 9, 2024, 4:30 PM EDT - 6 months ago

MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference

Aug 12, 2024, 7:05 AM EDT - 8 months ago

MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results

Aug 12, 2024, 7:03 AM EDT - 8 months ago

MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi

Jul 15, 2024, 11:02 AM EDT - 9 months ago

MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts

May 9, 2024, 8:00 AM EDT - 1 year ago

MeiraGTx Reports First Quarter 2024 Financial and Operational Results

Apr 24, 2024, 4:30 PM EDT - 1 year ago

MeiraGTx to Participate in Upcoming Investor Conferences

Apr 18, 2024, 4:30 PM EDT - 1 year ago

MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference

Mar 14, 2024, 8:30 AM EDT - 1 year ago

MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates

Feb 15, 2024, 8:23 AM EST - 1 year ago

MeiraGTx: Bota-Vec Program Advancing With Milestones Being Met

Dec 21, 2023, 7:00 AM EST - 1 year ago

MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million

Nov 14, 2023, 8:00 AM EST - 1 year ago

MeiraGTx Announces Third Quarter 2023 Financial and Operational Results

Oct 30, 2023, 8:28 AM EDT - 1 year ago

MeiraGTx shares jump as Sanofi invests in gene therapy

SNY

Oct 30, 2023, 7:30 AM EDT - 1 year ago

MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities

Oct 24, 2023, 8:30 AM EDT - 1 year ago

MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress

Aug 10, 2023, 8:00 AM EDT - 1 year ago

MeiraGTx Reports Second Quarter 2023 Financial and Operational Results

Aug 1, 2023, 9:10 AM EDT - 1 year ago

MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology

Jul 19, 2023, 8:30 AM EDT - 1 year ago

MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing

Jun 27, 2023, 7:30 AM EDT - 1 year ago

MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Jun 22, 2023, 4:01 PM EDT - 1 year ago

MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company's Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27,

May 11, 2023, 8:00 AM EDT - 2 years ago

MeiraGTx Reports First Quarter 2023 Financial and Operational Results

May 3, 2023, 8:30 AM EDT - 2 years ago

MeiraGTx Announces $60 Million Private Placement of Ordinary Shares

Apr 21, 2023, 8:30 AM EDT - 2 years ago

MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

Mar 14, 2023, 8:00 AM EDT - 2 years ago

MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results

Dec 8, 2022, 4:30 PM EST - 2 years ago

MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022

Oct 4, 2022, 8:00 AM EDT - 2 years ago

MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress

Oct 1, 2022, 10:00 AM EDT - 2 years ago

Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)

Sep 16, 2022, 2:00 AM EDT - 2 years ago

MeiraGTx's Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government

Aug 11, 2022, 8:30 AM EDT - 2 years ago

MeiraGTx Reports Second Quarter 2022 Financial and Operational Results

Aug 3, 2022, 8:00 AM EDT - 2 years ago

MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities

Jun 28, 2022, 7:00 AM EDT - 3 years ago

MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients treated with Botaretigene Sparoparvovec (AAV-RPGR) compared to

May 12, 2022, 8:00 AM EDT - 3 years ago

MeiraGTx Reports First Quarter 2022 Financial and Operational Results

May 4, 2022, 4:01 PM EDT - 3 years ago

MeiraGTx Presents Clinical Data on Botaretigene Sparoparvovec for the Treatment of X-Linked Retinitis Pigmentosa at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting

Apr 19, 2022, 4:30 PM EDT - 3 years ago

MeiraGTx to Participate in Upcoming Investor and Scientific Conferences

Mar 10, 2022, 8:00 AM EST - 3 years ago

MeiraGTx Reports Fourth Quarter and Full Year 2021 Financial and Operational Results

Jan 27, 2022, 8:30 AM EST - 3 years ago

MeiraGTx Receives Clinical Development Milestone Payment from Janssen

Dec 16, 2021, 3:49 PM EST - 3 years ago

A Biotech Unveils Its New Gene Control Technology

Dec 14, 2021, 4:30 PM EST - 3 years ago

MeiraGTx to Host a Virtual Research and Development Day on Gene Regulation

Dec 7, 2021, 8:59 AM EST - 3 years ago

MeiraGTx Reveals Interim Data From Phase 1 Trial Of Radiation-Induced Dry Mouth Symptom

Dec 7, 2021, 7:00 AM EST - 3 years ago

MeiraGTx Announces Positive Preliminary Data from the AQUAx Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Nov 29, 2021, 4:30 PM EST - 3 years ago

MeiraGTx to Provide a Xerostomia Clinical Program Update and Host a Virtual Research and Development Day on Gene Regulation

Nov 10, 2021, 8:00 AM EST - 3 years ago

MeiraGTx Reports Third Quarter 2021 Financial and Operational Results